Evidence map›Paper›PMID 28680965›Full record

ArticleeNeuro

A Brain-Derived Neurotrophic Factor-Based p75

David G Gonsalvez, Giang Tran, Jessica L Fletcher, Richard A Hughes, Suzanne Hodgkinson, Rhiannon J Wood, Sang Won Yoo, Mithraka De Silva, Wong W Agnes, Catriona McLean and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eNeuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

David G GonsalvezDepartment of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia.
Giang TranLiverpool Hospital, The University of New South Wales, NSW 2170, Australia.
Jessica L FletcherDepartment of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia.ORCID 0000-0003-2009-0798
Richard A HughesDepartment of Pharmacology and Therapeutics, The University of Melbourne, VIC 3010, Australia.
Suzanne HodgkinsonLiverpool Hospital, The University of New South Wales, NSW 2170, Australia.
Rhiannon J WoodDepartment of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia.
Sang Won YooDepartment of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia.
Mithraka De SilvaDepartment of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia.
Wong W AgnesDepartment of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia.
Catriona McLeanVictorian Neuromuscular Laboratory Services, Alfred Health, VIC 3004, Australia.
Paul KennedyVictorian Neuromuscular Laboratory Services, Alfred Health, VIC 3004, Australia.
Trevor J KilpatrickDepartment of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia.ORCID 0000-0003-3999-085X
Simon S MurrayDepartment of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia.ORCID 0000-0001-6671-192X
Junhua XiaoDepartment of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia.ORCID 0000-0002-4320-2855
The University of Melbourne · AUAlfred Health · AULiverpool Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Axonal damage and demyelination are major determinants of disability in patients with peripheral demyelinating neuropathies. The neurotrophin family of growth factors are essential for the normal development and myelination of the peripheral nervous system (PNS), and as such are potential therapeutic candidates for ameliorating axonal and myelin damage. In particular, BDNF promotes peripheral nerve myelination via p75 neurotrophin receptor (p75

Indexed as

Neuritis, Autoimmune, ExperimentalAmyloid beta-Protein PrecursorAnimalsAxonsDemyelinating DiseasesDisease Models, AnimalDose-Response Relationship, DrugFemaleGene Expression RegulationMiceMice, Inbred C57BLMicroscopy, ConfocalMicroscopy, Electron, TransmissionMyelin Basic ProteinOligopeptidesRatsAmyloid beta-Protein PrecursorMyelin Basic ProteinNgfr protein, mouseOligopeptidesReceptors, Nerve Growth FactorRNA, Messengeraxonal damageBDNFdemyelinationexperimental autoimmune neuritisp75NTR

Identifiers

PMID28680965
PMCPMC5496185
OpenAlexW2729641094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.